Trial Evaluates Reduced Chemo Post-Stem Cell Transplant in Blood Cancers
February 26, 2024
The first patient has been enrolled in a Phase II clinical trial evaluating a reduced dose of a post-transplant immunosuppressive chemotherapy treatment after stem cell transplantation for patients with certain blood cancers. The trial is starting at OHSU and principal investigator Rachel Cook, M.D., says: "I am thrilled about the initiation of the OPTIMIZE clinical trial, which represents a significant advance in blood cancer treatment by exploring the potential of reduced dose PTCy to mitigate adverse effects and ensure broader treatment inclusivity. This trial is a step towards significantly improving patient outcomes by aiming for more personalized and less toxic treatment protocols.”